Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06465277
Other study ID # awaited
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 21, 2023
Est. completion date November 2024

Study information

Verified date June 2024
Source Belfast Health and Social Care Trust
Contact Adam Glass
Phone +442890976378
Email a.glass@qub.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Feasibility study investigating CMR dobutamine stress testing before and after lung resection


Description:

We hypothesise that following lung resection, 1. the subtle decrease in RV function and increase in afterload we have demonstrated at rest is associated with a marked impairment of RV function on exercise, termed impaired RV contractile reserve (RVCreserve), 2. impaired RVCreserve is associated with impaired functional capacity . In this study we aim to assess the feasibility of dobutamine stress cardiovascular magnetic resonance (CMR) scanning to assess RVCreserve pre- and post-operatively in patients undergoing lung resection. Additionally, we hypothesise that one lung ventilation (with and without lung resection) is associated with biomarker evidence of RV injury.We will perform peri-operative cardiac biomarkers to differentiate between the contribution of major surgery (gastrectomy, lung resection and oesophagectomy), one lung ventilation (lung resection and oesophagectomy) and lung resection on RV injury.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date November 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1) Provision of informed consent 2) Age >16 years 3) Planned elective 1. lobectomy lung resection or 2. oesophagectomy surgery with one lung ventilation or 3. gastrectomy Exclusion Criteria: 1. Pregnancy 2. On-going participation in any investigational research which could undermine the scientific basis of the study 3. Atrial fibrillation at baseline 4. Any contraindication to a. CMR, i. Cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. Aneurysm clips iii. Metal injuries to the eye iv. Loose metal in a part of the body b. Dobutamine stress testing as per the Society for Cardiovascular Magnetic Resonance64 i. Severe systemic arterial hypertension (=220/120 mmHg) ii. Unstable angina pectoris iii. Severe aortic valve stenosis (peak aortic valve gradient >60mmHg or aortic valve area < 1cm2) iv. Complex cardiac arrhythmias including uncontrolled atrial fibrillation v. Hypertrophic obstructive cardiomyopathy vi. Myocarditis, endocarditis, or pericarditis vii. Uncontrolled heart failure 5. Lung resection specific 1. Wedge, segmental or sub-lobar lung resection 2. Pneumonectomy 3. Isolated right middle lobectomy -

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Dobutamine stress CMR
Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines. At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries. Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team.
Cardiac biomarker sample
blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively

Locations

Country Name City State
United Kingdom Belfast Health and Social Care Trust Belfast Northern Ireland

Sponsors (1)

Lead Sponsor Collaborator
Belfast Health and Social Care Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1) Feasibility of dobutamine stress CMR to measure RVCreserve following lung resection. Reliability and variability will be assessed through dual reporting of the CMR images, testing intra-/inter-observer intraclass correlation coefficient (ICC) and coefficient of variation (CV). Study design will allow comparison to our previous resting studies published exercise literature and between pre- and post-operative imaging. Pre-operative and 2 months post-operative
Secondary 1) Acceptability of the dobutamine stress CMR protocol to patients, by questionnaire Assessed by patient satisfaction questionnaires rate compared to our previous CMR studies that were performed without dobutamine stress testing. Pre-operative and 2 months post-operative
Secondary 1) Acceptability of the dobutamine stress CMR protocol to patients, by completion Assessed by patient recruitment/withdrawal rate compared to our previous CMR studies that were performed without dobutamine stress testing. Pre-operative and 2 months post-operative
Secondary 2) Incidence of complications related to dobutamine stress CMR We will assess for the onset of any of the following during the scan
New onset atrial fibrillation
Ventricular tachycardia
Angina, chest pain, shortness of breath and/or ischaemic ECG changes
Pre-operative and 2 months post-operative
Secondary 3) Change in RVCreserve change following lung resection Comparison of the change in RVEF on stress pre- and post-operatively Pre-operative and 2 months post-operative
Secondary 4) Change in PVreserve change following lung resection Comparison of change in wave reflection on stress pre- and post-operatively Pre-operative and 2 months post-operative
Secondary 5) Association between the changes in RVCreserve and markers of cardiac inflammation, BNP Comparison of change in RVCreserve and the change in BNP Pre-operative and 2 months post-operative
Secondary 5) Association between the changes in RVCreserve and markers of cardiac inflammation, hsTnT Comparison of change in RVCreserve and the change in hsTnT. Pre-operative and 2 months post-operative
Secondary 1) Post-operative change in BNP Post-operative change in BNP in oesophagectomy compared to lung resection and gastrectomy. Peri-operative blood samples, pre-op, immediately post-op, post-op days 1 and 2, 4-8 weeks post-op
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk